About
GT Apeiron Therapeutics is a clinical-stage small molecule biotech company based in Shanghai and San Francisco, developing biomarker-driven cancer therapeutics including a PRMT5 inhibitor in Phase 1 clinical trials and a KIF18A inhibitor with a differentiated profile.
Explore GT Apeiron Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.